Dual Promoter Systems - Seattle Children's Hospital - EP4149966A1

The European Patent Office published European patent application EP4149966A1 for 'Dual Promoter Systems' on April 15, 2026. The application, filed by Seattle Children's Hospital (DBA Seattle Children's Research Institute), names Michael C. Jensen and Jia Wei as inventors. The technology is classified under IPC class C07K covering peptides and proteins, with particular focus on C07K 14/705 (peptides with more than 20 amino acids) and C07K 19/00 (hybrid peptides). The application designates 31 European states including major jurisdictions such as Germany, France, the United Kingdom, the Netherlands, Italy, and Spain.

For biotechnology and pharmaceutical companies developing gene therapy or immunotherapy products employing dual promoter constructs, this patent publication establishes a prior art date of April 15, 2026. Companies with similar technologies should review their freedom-to-operate position and consider whether their constructs fall within the scope of the claimed dual promoter systems. The designated states include all major European patent validation countries, making this geographically significant for anyone seeking to commercialize related products in the EU market.